Patents Examined by Theodore J. Criares
  • Methods and compositions for treating male erectile dysfunction
    Patent number: 6414027
    Abstract: Administration of a pharmaceutical composition in the form of a suppository comprising: (a) a prostaglandin vasodilator; (b) 15-hydroxyprostaglandindehydrogenase inhibitor; and (c) a base material that is solid at room temperature and releases components (a) and (b) when inserted in the urethra, is effective for the treatment of male erectile dysfunction.
    Type: Grant
    Filed: December 18, 1998
    Date of Patent: July 2, 2002
    Assignee: Androsolutions, Inc.
    Inventor: Gary W. Neal
  • Methods for inhibiting bone resorption
    Patent number: 6414006
    Abstract: The present invention relates to methods for inhibiting bone resorption in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of an EP4 receptor subtype antagonist.
    Type: Grant
    Filed: October 13, 1999
    Date of Patent: July 2, 2002
    Assignees: Merck Frosst Canada & Co., Merck & Co., Inc.
    Inventors: Shun-ichi Harada, Gideon A. Rodan, Mohamed Machwate, Marc LaBelle, Kathleen Metters, Robert N. Young
  • Methods and compositions for treating male erectile dysfunction
    Patent number: 6410595
    Abstract: Administration of a pharmaceutical composition comprising: (a) a vasodilator; and (b) a 15-hydroxyprostaglandindehydrogenase inhibitor is effective for the treatment of male erectile dysfunction.
    Type: Grant
    Filed: October 12, 1999
    Date of Patent: June 25, 2002
    Assignee: Androsolutions, Inc.
    Inventor: Gary W. Neal
  • Combination therapy for the treatment of benign prostatic hyperplasia
    Patent number: 6410554
    Abstract: This invention relates to combination therapy for the treatment of benign prostatic hyperplasia comprising an alpha-1a antagonist and an endothelin antagonist. More specifically, the use of a selective alpha-1a adrenergic receptor antagonist in combination with a subtype non-selective endothelin antagonist provides relief of lower urinary tract symptoms in patients with symptomatic prostatism or benign prostatic hyperplasia. This combination therapy improves lower urinary tract symptoms including increasing urine flow rate, decreasing residual urine volume and improving overall obstructive and irritative symptoms in patients with benign prostatic hyperplasia or symptomatic prostatism.
    Type: Grant
    Filed: March 23, 1999
    Date of Patent: June 25, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Theodore P. Broten, Peter K. S. Siegl, Steven A. Nichtberger
  • Lipid lowering quinazoline dietary supplement composition
    Patent number: 6410545
    Abstract: A novel carbonyl-substituted quinazoline, preferably 4-(3′-bromobenzoyl)-6,7-dimethoxyquinazoline (WHI-P164), and methods for lowering blood cholesterol, including reducing total cholesterol and LDL-cholesterol levels by administration of the carbonyl quinazolines and compositions thereof.
    Type: Grant
    Filed: June 26, 2001
    Date of Patent: June 25, 2002
    Assignee: Parker Hughes Institute
    Inventors: Fatih M. Uckun, Vuong N. Trieu, Xing-Ping Liu
  • Methods of modulating matrix metalloproteinase activity and uses thereof
    Patent number: 6403637
    Abstract: Methods for inactivating matrix metalloproteinases in a vertebrate cell are disclosed. The methods comprise administering to the cell an agent which causes increased endocytosis of the matrix metalloproteinase. Methods for treating vertebrates with disorders mediated by matrix metalloproteinases are also disclosed. These methods comprise administering the above-described agents to the vertebrate. Also disclosed is the use of HMG-CoA reductase inhibitors, also known as statins, as an agent which causes increased endocytosis of matrix metalloproteinases. Assays for determining whether an agent is effective in treating a disorder are also disclosed. These assays comprise testing the agent for activity in increasing endocytosis of a matrix metalloproteinase which mediates the disorder.
    Type: Grant
    Filed: August 9, 1999
    Date of Patent: June 11, 2002
    Inventor: Nicola C. Partridge
  • Corticotropin releasing factor antagonists
    Patent number: 6403599
    Abstract: A method of treating, preventing or inhibiting a disorder selected from the group consisting of cardiovascular or heart related diseases such as stroke, hypertension, tachycardia, and congestive heart failure, osteoporosis, premature birth, psychosocial dwarfism, stress-induced fever, ulcer, diarrhea, post-operative ileus, and colonic hypersensitivity associated with psychopathological disturbance and stress, comprising administering to a mammal, including a human, in need of such treatment a therapeutically effective amount of a compound of the formula or a pharmaceutically acceptable salt thereof, wherein A, B, D, E, Y, Z, R3, R4, and R5 are as defined herein.
    Type: Grant
    Filed: October 30, 1996
    Date of Patent: June 11, 2002
    Assignee: Pfizer Inc
    Inventors: Yuhpyng L. Chen, Anthony A. Fossa
  • 2-Aryl-3-aroylbenzo {b} thiophenes useful for the treatment of estrogen deprivation syndrome
    Patent number: 6403615
    Abstract: This invention provides methods which are useful for the inhibition of the various medical conditions associated with estrogen deprivation syndrome including osteoporosis and hyperlipidemia utilizing compounds of formula I:
    Type: Grant
    Filed: September 29, 2000
    Date of Patent: June 11, 2002
    Assignee: Eli Lilly and Company
    Inventor: George Joseph Cullinan
  • Use of 2,5-dihydroxybenzenesulfonic derivatives for the normalization of endothelial function
    Patent number: 6403643
    Abstract: A method for the use of 2,5-dihydroxybenzenesulfonic derivatives for normalizing endothelial function is disclosed. Preferred 2,5-dihydroxybenzenesulfonic derivatives are calcium dobesilate, ethamsylate and persilate.
    Type: Grant
    Filed: July 26, 2000
    Date of Patent: June 11, 2002
    Assignee: Laboratories del Dr. Esteve, S.A.
    Inventor: Jose Esteve-Soler
  • Therapeutic usage of tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
    Patent number: 6399609
    Abstract: Corticotropin releasing factor (CRF) antagonists of formula I: and their use in treating anxiety, depression, and other psychiatric and neurological disorders.
    Type: Grant
    Filed: May 11, 2000
    Date of Patent: June 4, 2002
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventor: Richard Gerald Wilde
  • Bishphosphonate/estrogen synergistic therapy for treating and preventing bone loss
    Patent number: 6399592
    Abstract: Disclosed is a combination therapy for treating and for preventing bone loss by the use of estrogen and a bisphosphonate selected from: alendronate, clodronate, tiludronate, YM175, BM 210995, or mixture thereof. Also described is a pharmaceutical composition of the above for carrying out the therapeutic method.
    Type: Grant
    Filed: June 23, 1997
    Date of Patent: June 4, 2002
    Assignee: Merck & Co., Inc.
    Inventor: Donna T. Whiteford
  • Pharmaceutical preparation for the treatment of inflammatory processes
    Patent number: 6399572
    Abstract: A pharmaceutical preparation is described while is useful for the treatment of inflammatory processes being accompanied by an increased distribution of cytokines and/or tissue factor in the human body, which preparation contains Antithrombin III as active ingredient.
    Type: Grant
    Filed: January 28, 2000
    Date of Patent: June 4, 2002
    Assignee: Aventis Behring GmbH
    Inventors: Jürgen Römisch, Gerhard Dickneite, Peter Gronski, Bernhard Vohwinkel, Harald Stauss, Elaine Gray, Pauline Sxouter, Stephen Poole
  • Uses for indole-3-propionic acids and salts and esters thereof
    Patent number: 6395768
    Abstract: The cytotoxic effects of amyloid beta protein on cells are prevented by contacting the cells with an effective amount of an indole-3-propionic acid or a salt or ester thereof. Furthermore, a fibrillogenic disease can be treated in a human subject by administering to the human subject an amount of-an indole-3-propionic acid or a salt or ester thereof effective to prevent or reverse fibrillogenesis. Oxidation in a biological sample can be decreased by contacting the biological sample with an effective amount of an indole-3-propionic acid or a salt or ester thereof. Additionally, diseases or other conditions where free radicals and/or oxidative stress play a role can be treated by administering an effective amount of an indole-3-propionic acid or a salt or ester thereof.
    Type: Grant
    Filed: May 30, 2000
    Date of Patent: May 28, 2002
    Assignees: South Alabama Medical Science Foundation, New York University
    Inventors: Miguel A. Pappolla, Blas Frangione, Jorge Ghiso, Burkhard Poeggeler
  • 2-arylbenzo[b]thiophenes useful for the treatment of estrogen deprivation syndrome
    Patent number: 6395769
    Abstract: This invention provides methods which are useful for the inhibition of the various medical conditions associated with estrogen deprivation syndrome including osteoporosis and hyperlipidemia utilizing compounds of formula I:
    Type: Grant
    Filed: May 12, 2000
    Date of Patent: May 28, 2002
    Assignee: Eli Lilly and Company
    Inventor: George Joseph Cullinan
  • Method for preventing diarrhea
    Patent number: 6395708
    Abstract: The present invention relates to a method for preventing irinotecan-induced or camptothecin-induced or camptothecin- analog-induced diarrhea by administering an effective amount of octreotide. In particular the invention concerns new methods, combination formulations and kits to prevent late diarrhea caused by irinotecan or camptothecin, or camptothecin-analog administration.
    Type: Grant
    Filed: August 25, 2000
    Date of Patent: May 28, 2002
    Assignees: Novartis, A.G., Pharmacia & Upjohn Co.
    Inventors: Langdon L. Miller, John David Rothermel, Hugh Michael O'Dowd
  • Method of treating Bulimia Nervosa and related eating disorders by administration of atypical antipsychotic medications
    Patent number: 6395727
    Abstract: The invention relates to a method of treating non-psychotic disorders by administration of atypical antipsychotic medications, in particular, risperidone. More specifically, the invention relates to a method of treating the eating disorder Bulimia Nervosa and Bulimia-related eating disorders, by administration of antipsychotic medications from the group of compounds designated as atypical antipsychotic mediations. Typical dosage amounts may range from 0.1 milligrams to 4 milligrams per day and may be administered in any dosage forms known in the art, including, but not limited to oral, intramuscular, rectal, transdermal, sustained release forms, controlled release forms, delayed release forms, and response release forms.
    Type: Grant
    Filed: March 17, 2000
    Date of Patent: May 28, 2002
    Assignee: The Cincinnati Children's Hospital Research Foundation
    Inventors: Gina Guadagno, Jodi M. Star
  • Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
    Patent number: 6391922
    Abstract: The present invention describes a novel treatment for neuropsychiatric disorders, including anxiety disorders, mood disorders, psychotic disorders, somatoform disorders, and neuropsychiatric symptoms resulting from movement disorders. The treatment of the present invention utilizes any agent that simultaneously act as NMDA-type glutamate receptor antagonists and GABA-A receptor agonists. Preferably these two activities are characteristic of a single agent, for example acamprosate (calcium N-acetylhomotaurinate). Alternatively, separate agents having these activities can be combined as a compound or mixture and thereby administered together. The invention also provides for a third agent that acts as a non-competitive NMDA-receptor blocking agent or ion channel blocker, that augments the effect of the primary treatment. A particularly preferred ion channel blocking agent is magnesium.
    Type: Grant
    Filed: March 19, 1999
    Date of Patent: May 21, 2002
    Assignee: Synchroneuron, LLC
    Inventor: Barry S. Fogel
  • Pharmaceutical composition
    Patent number: 6387918
    Abstract: A pharmaceutical composition comprising a tricyclic compound (I) or its pharmaceutically acceptable salt, an oil substance, a surfactant, a hydrophilic substance, water, and optionally a pH control agent, with enhanced stability, absorbability and/or a low irritation potential, is provided.
    Type: Grant
    Filed: August 20, 1999
    Date of Patent: May 14, 2002
    Assignee: Fujisawa Pharmaceutical Co., Ltd.
    Inventors: Masayuki Yamanaka, Fumio Shimojo, Satoshi Ueda, Toshihiko Toyoda, Rinta Ibuki, Norio Ohnishi
  • QT dispersion and heart rate variability improvement with CRF antagonists to prevent sudden death
    Patent number: 6384039
    Abstract: A method of preventing sudden death which comprises administering to a mammal, including a human, a therapeutically effective amount of a corticotropin releasing factor antagonist.
    Type: Grant
    Filed: March 31, 2000
    Date of Patent: May 7, 2002
    Assignee: Pfizer Inc.
    Inventor: Anthony A. Fossa
  • Method for treating and preventing hyperparathyroidism
    Patent number: 6376479
    Abstract: A method for reducing or preventing elevated blood parathyroid hormone level in a human being suffering from primary hyperparathyroidism, secondary hyperparathyroidism, or hyperparathyroidism secondary to end stage renal disease by administering a sufficient amount of 1&agr;,24(S)-(OH)2 vitamin D2.
    Type: Grant
    Filed: February 9, 2000
    Date of Patent: April 23, 2002
    Assignee: Bone Care International, Inc.
    Inventors: Joyce C Knutson, Charles W. Bishop